鈉–葡萄糖協(xié)同轉運蛋白2（SGLT2）抑制劑是近年來上市的一種新型降糖藥物，主要通過抑制表達于腎臟近曲小管處的SGLT2來阻止腎臟對葡萄糖的重吸收，從而通過排出糖尿來降低血糖。除降糖作用外，SGLT2抑制劑同時有心血管保護、抑制炎癥和氧化應激、改善腎臟疾病預后等多種作用。研究發(fā)現(xiàn)SGLT2在多種類型的腫瘤中表達，并可能參與癌細胞對葡萄糖的攝取和利用，抑制這種轉運蛋白可以抑制腫瘤的生長。SGLT2被推測有可能成為特定癌癥的一種新的腫瘤標志物，而SGLT2抑制劑有望成為一種新的靶向調節(jié)葡萄糖攝取的抗腫瘤藥物。因此對目前研究關注最多的SGLT2抑制劑對肝癌、乳腺癌、宮頸癌、肺癌、結直腸癌、腎細胞癌、膀胱癌的影響進行了綜述。

Sodium glucose cotransporter 2 (SGLT2) inhibitor is a novel hypoglycemic drug marketed in recent years. It mainly inhibits the reabsorption of glucose by the kidney by inhibiting the expression of SGLT2 in the proximal convoluting tubule of the kidney, thus reducing blood glucose by excreting sugar and urine. Studies have shown that in addition to the hypoglycemic effect, such drugs as well as cardiovascular protection, inhibiting inflammation and oxidative stress, improving the prognosis of kidney disease and other effects, and the study found that SGLT2 expressed in various types of cancer, and may participate in the cancer cells to glucose uptake and utilization of inhibiting the transporters can inhibit tumor growth. Therefore, SGLT2 is speculated to be a new tumor marker for specific cancers, and SGLT2 inhibitors are expected to become new anti-tumor drugs targeting glucose uptake regulation. This article reviews the research on the effect of SGLT2 inhibitors on liver cancer, breast cancer, cervical cancer, lung cancer, colorectal cancer, renal cell cancer, and bladder cancer.

R979.1